Open Monoclonal Technology
	Developer of human monoclonal antibody platforms. The company develops human therapeutic antibodies based on transgenic rats for pharmaceutical companies.
	['', 'human monoclonal', ' ', 'antibody platform', ' ', 'transgenic rat', '']
GLYCART Biotechnology
	Developer of antibody based products for the treatment of unmet clinical needs such as cancer. The company focuses on the development and commercialization of a new generation of antibody products based on its proprietary GlycoMAb technology.
	['antibody ', 'antibody products', '']
Centocor
	Developer of monoclonal antibody technology. The company develops monoclonal antibody-based products for cardiovascular and autoimmune diseases, cancer and inflammation.
	['', 'monoclonal antibody technology', ' ', 'autoimmune disease', ' biopharmaceutical']
Merrimack Pharmaceuticals
	Provider of commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The company develops MM-093, a human alpha-fetoprotein for the treatment of patients with rheumatoid arthritis and psoriasis and MM-121, a human monoclonal antibody and therapeutic to block signaling of the ErbB3 receptor.
	['', 'commercial medicine', ' ', 'diagnostic treatment', ' cancer']
FivePrime Therapeutics
	Developer of protein and antibody therapeutics. The company\'s products include protein based therapeutics for oncology, metabolic disease, type II diabetes, acute myocardial infarction, intestinal bowel disease and infectious diseases and cancer immunotherapy disease areas.
	['', 'antibody therapeutic', ' ', 'cancer immunotherapy', ' ', 'protein therapeutic', '']
4-Antibody
	Developer of an antibody drug discovery platform. The company is a biopharmaceutical enterprise developing a fully human, antibody drug discovery platform. The company is making this technology available to pharmaceutical partners, as well as developing a proprietary pipeline of antibody oncology drugs.
	['', 'discovery technology platform', ' immunotherapy ', 'antibody drug', '']
Affomix
	Developer of antibody-based products.
	['', 'antibody screening', ' ', 'antibody product', ' ', 'antibody preparation', '']
UroTec
	Provider of tissue-engineering services for the treatment of urologic disease. The company focuses on treatment of urethral stricture, ureteral strictures, ureteral anomalies and hypospadia.
	['', 'urologic disease', ' ', 'urethral stricture', ' hypospadia ', 'tissue engineering', '']
BioInvent
	Developer of antibody-based drug therapies for the treatment of cancer. The company has a pipeline of three proprietary antibodies focused on treatment for multiple myeloma, non-Hodgkin lymphoma and medulloblastoma.
	['', 'antibody drugs', ' ', 'drug developer', ' ', 'multiple myeloma', ' ', 'non-Hodgkin lymphoma', '']
Automated Cell
	Developer of antibody therapeutic antibodies for the treatment of oncology and immune disease. The company is focused on the development of monoclonal antibody therapeutics for the treatment of cancer.
	['', 'antibody therapeutic', ' ', 'therapeutic treatment', ' ', 'oncology disease', ' ', 'immune disease', ' ', 'monoclonal antibody', '']
Applied Genomics
	Developer of targeted genomics-based diagnostic and therapeutic antibodies for the treatment of human cancer. The company\'s products include Mammostrat which is an immunohistochemistry breast cancer prognostic test, Mammotax which is a single antibody immunohistochemistry test, Pulmotype is a five antibody immunohistochemistry aid for the classification of non-small cell lung cancer and Pulmostrat is a seven antibody prognostic immunohistochemistry test.
	['', 'human cancer', ' ', 'therapeutic antibodies', ' ', 'diagnostic devices', '']
GITR
	Developer of oncological therapies. The company is developing TRX518, a humanized monoclonal antibody that is reactive with the glucocorticoid-induced tumor necrosis factor receptor (GITR), for the treatment of cancer.
	['', 'chemotherapeutic treatment', ' ', 'tumor markers', ' ', 'T cell', '']
Immunologix
	Developer of antibody-based therapeutics. The company provides methods for producing human monoclonal antibodies against any target including bacterial and viral antigens, as well as tumor antigens, and human autoantigens. Its technology allows for the conversion of na√Øve B-cells (from a tonsillectomy or whole blood collection) to fully mature human B-cells producing the human antibody of interest.
	['', 'antibody therapeutic', ' ', 'human monoclonal', ' ', 'therapeutic device', '']
